caa a22 4500 465789536 CHVBK 20180323112019.0 cr unu---uuuuu 170327e19900801xx s 000 0 eng 10.1007/BF00171837 doi (NATIONALLICENCE)springer-10.1007/BF00171837 Phase I study of idarubicin administered orally on a daily × 3 schedule [Elektronische Daten] [David Stewart, Shailendra Verma, Jean Maroun, Lucille Robillard, Daniele Perrault, Vincent Young, Sunil Gupta, Betty Fontaine] Summary: Twenty-one adult patients with refractory solid tumors were treated on a phase I study of idarubicin (4-demethoxydaunorubicin) administered daily for 3 days every 3 weeks. Nineteen of the patients had received previous chemotherapy (including 13 with prior anthracyclines), and 12 had received prior radiotherapy. Idarubicin dose levels of 10, 15, 17.5, 20, and 25 mg/m2 were explored. Hematological toxicity was dose-related. Other toxicity was acceptable. Only one patient (treated with an idarubicin dose of 17.5 mg/m2/day) developed neutropenic fever, from which he recovered. Further dose escalations beyond 25 mg/m2 were not carried out because of the increasing length of time required for recovery from granulocytopenia at higher doses. No patient experienced a major response, but minor responses were seen in 3 patients with carcinomas of the colon, breast, and kidney respectively. Further phase II studies of oral idarubicin at a starting dose of 20-25 mg/m2 daily times 3 days in patients with good bone marrow reserves are recommended. Because of the degree of neutropenia expected, patients would have to be observed carefully. Kluwer Academic Publishers, 1990 idarubicin nationallicence phase I nationallicence oral nationallicence Stewart David Ottawa Regional Cancer Centre, 190 Melrose Ave, K1Y 4K7, Ottawa, Ontario, Canada aut Verma Shailendra aut Maroun Jean aut Robillard Lucille aut Perrault Daniele aut Young Vincent aut Gupta Sunil aut Fontaine Betty aut Investigational New Drugs Kluwer Academic Publishers 8/3(1990-08-01), 275-281 0167-6997 8:3<275 1990 8 10637 https://doi.org/10.1007/BF00171837 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/BF00171837 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Stewart David Ottawa Regional Cancer Centre, 190 Melrose Ave, K1Y 4K7, Ottawa, Ontario, Canada aut NATIONALLICENCE 700 1- Verma Shailendra aut NATIONALLICENCE 700 1- Maroun Jean aut NATIONALLICENCE 700 1- Robillard Lucille aut NATIONALLICENCE 700 1- Perrault Daniele aut NATIONALLICENCE 700 1- Young Vincent aut NATIONALLICENCE 700 1- Gupta Sunil aut NATIONALLICENCE 700 1- Fontaine Betty aut NATIONALLICENCE 773 0- Investigational New Drugs Kluwer Academic Publishers 8/3(1990-08-01), 275-281 0167-6997 8:3<275 1990 8 10637 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer